SOPHiA GENETICS Announces Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study | State

BOSTON and LAUSANNE, Switzerland, January 11, 2022 / CNW / – SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data and knowledge sharing platform that advances data-driven medicine, today announced strong traction in the launch phase of its DEEP-Lung-IV clinical study (NCT04994795). Since its official launch last month, 12 sites in 5 countries have already registered to participate in the study.

Despite the clinical promises of immunotherapy, significant challenges remain as the majority of patients with non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors. Today, PD-L1 is the only standard predictive biomarker for the efficacy of immune checkpoint inhibitors, but it remains a very suboptimal biomarker with several well characterized problems limiting its clinical utility. Thus, there is an urgent need to discover new biomarkers predictive of response to immunotherapy. SOPHiA GENETICS ‘DEEP-Lung-IV clinical study relies on deep learning analysis of real-world multimodal data aggregation (including genomic, radiomic and clinical data) to identify and validate predictive signatures associated with the response to immunotherapy and the prognosis of patients with metastatic NSCLC (stage IV). Such signatures could help identify which patients may benefit from immunotherapy versus those who do not, as well as stratify patients based on risk, helping clinicians make more informed treatment decisions for their patients and supporting biopharma to ensure the right patients are selected for the clinic. testing.

The initial 12 sites that signed up to participate in the study include the Carbon Comprehensive Cancer Center in University of Wisconsin and Holden Comprehensive Cancer Center at University of Iowa Health Care in the United States, Public Assistance-Hospitals of Paris and Hospices Civils de Lyonnais in France, Leipzig University of Germany, Sunnybrook Health Sciences Center at Toronto, Canada, and Shaare Zedek Medical Center in Jerusalem, Israel, among others. Together, these sites are expected to contribute more than 2,000 of the 4,000 total patients targeted for enrollment during the study. 10 additional sites are awaiting integration in the first quarter of 2022, with more candidates expected to follow.

“We are very pleased with the strong traction since the launch of our multimodal DEEP-Lung-IV clinical study. The positive reception from participating sites highlights the great interest in unleashing the predictive potential of multimodal health data sets through large-scale real-world studies “said Dr Jurgi Camblong, co-founder and CEO of SOPHiA GENETICS. “We look forward to further accelerating this momentum in the first months of 2022.”

To learn more about the DEEP-Lung-IV clinical study, visit


SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for research in the life sciences. He is the creator of the SOPHiA DDM ™ platform, a cloud-based SaaS platform capable of analyzing data and generating information from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM ™ platform and associated solutions, products and services are currently used by more than 790 hospitals, laboratories and biopharmaceutical institutions around the world. For more information, visit SOPHiAGENETICS.COM, or log on to Twitter, LinkedIn and Instagram. Where others see data, we see answers.

SOPHiA GENETICS forward-looking statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding our future results of operations and financial condition, business strategy, products and technology, and plans and objectives of management for future transactions, are forward-looking statements. . Forward-looking statements are based on the beliefs and assumptions of our management and on information currently available to our management. These statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in forward-looking statements due to various factors, including those described in our documents filed with the Securities and Exchange Commission. the United States. No assurance can be given that such future results will be achieved. These forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or commitment to update any forward-looking statements contained in this press release to reflect any change in our expectations or any change in the events, conditions or circumstances upon which such statements are based, unless it is required by law. No representation or warranty (express or implied) is made as to the accuracy of these forward-looking statements.

View original content to download multimedia: -multimodal -clinical-study-301457716.html


Comments are closed.